Big Pharma Answers Price Cuts the Only Way It Knows How: A Record Lobbying Blitz
Drug companies in the TrumpRx program boosted federal lobbying spending by nearly 23 percent as Washington squeezed their prices.

When Washington finally came for drug prices, Big Pharma did not respond with lower list prices and a humble apology. It responded with cash, and a lot of it.
According to lobbying disclosures analyzed by Truthout, the 17 pharmaceutical companies participating in the TrumpRx pricing program spent more than 130 million dollars on federal lobbying in 2025. That is a nearly 23 percent jump from the 109 million dollars those same firms spent in 2024, and it happened in the run up to the February launch of the TrumpRx site.
Those 17 firms alone accounted for more than a quarter of the record 457.3 million dollars the industry spent on federal lobbying in 2025. And the spigot is still open: first quarter spending in 2026 topped 131 million dollars industry wide, up 5.7 percent from a year earlier.
The pattern is not subtle. Bristol Myers Squibb, whose blood thinner Eliquis faced a 56 percent price cut, boosted its lobbying 84 percent to more than 10 million dollars. AstraZeneca, whose diabetes drug Farxiga saw a 68 percent discount, increased spending 55 percent to 5.8 million dollars. Eli Lilly and Novo Nordisk, the giants behind the blockbuster weight loss injectables, spent 11.2 million dollars and more than 7.23 million dollars respectively.
Olivier Wouters, a researcher at Brown University who studies the industry, summed it up: all he could say was that they are spending a ton of money. The companies focused their firepower on measures like the Pill Penalty bills and legislation governing coverage of the new obesity drugs.
Remember the sequence here. These companies signed voluntary agreements to give Americans most favored nation pricing, then immediately poured record sums into influencing the very government they made the deals with. In exchange for the discounts, participating firms received multiyear tariff exemptions running through January 2029. That is not a market. That is a negotiation between a government and a cartel, with lobbyists as the couriers.
MediaMogul takes no pharmaceutical advertising, so we can say what the ad funded networks will not. An industry that spends nearly half a billion dollars a year lobbying Congress is not betting on the quality of its science. It is betting on the price of your representatives. Every dollar of that record haul was built into the price of somebody's prescription.
Watch the disclosures, not the press releases. The lobbying numbers tell you what Big Pharma actually fears, and right now it fears losing control of the price.
Sources
Questions readers ask
What is Media Mogul News?
Media Mogul News is an independent, reader-supported news site led by Chief Editor Nate Jurewicz. We cover the stories corporate media skips: political corruption, Big Pharma, the deep state, election integrity, cannabis freedom, crypto and the money behind all of it.
What is your political stance?
We are pro-liberty, pro-cannabis, anti-war and anti-corruption, and we hold both parties to the same standard. We are not a party outlet. When the people we agree with get something wrong, we say so.
How is Media Mogul funded?
By readers. We take no pharmaceutical advertising and no money from the industries we cover. Support comes from newsletter readers, donations and Media Mogul merchandise.
